# India Thalassemia Market

> India Thalassemia Market Research Report Information by Type (Alpha-thalassemia and Beta-thalassemia) and by Treatment & Diagnosis (Treatment [Blood Transfusions, Drugs, Folic Acid Supplements] and Diagnosis [Instruments and Reagents) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.85%
- **2024:** $ 175 Million
- **2025:** $ 184.5 Million
- **2035:** $ 294.5 Million
- **Key Players:** Bristol Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer (US), Bayer (DE), Amgen (US), Sanofi (FR), Celgene (US), GSK (GB)

**Report ID:** MRFR/HC/20454-CR · **Pages:** 208 · **Author:** Rahul Gotadki · **Last Updated:** April 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-thalassemia-market-22054

---

## Market Summary

## **India Thalassemia Market Overview**

As per MRFR analysis, the India Thalassemia Market Size was estimated at 0.22 (USD Billion) in 2024. The India Thalassemia Market Industry is expected to grow from 0.23 (USD Billion) in 2025 to 0.36 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.03% during the forecast period (2025 - 2034).

Growing government initiatives and support to raise awareness for thalassemia and increased prevalence of thalassemia in India are fueling the growth of the India thalassemia market.

** Source: Secondary Research, Primary Research, MRFR Database and Analyst Review**

## **India Thalassemia Market Trends**

In recent years, the Indian government has taken significant steps towards raising awareness for thalassemia, a genetic blood disorder that affects a large number of people in the country. Government initiatives have played a crucial role in educating the public about thalassemia and its prevention methods. The Ministry of Health and Family Welfare has been actively involved in implementing various programs and campaigns to increase knowledge and understanding of this condition. For instance, in May 2023, Ministry of Health and Family Welfare (India) reported that Dr Bharati Pravin Pawar launched Phase-III of Thalassemia Bal Sewa Yojana.

Furthermore, it also stated that combating blood disorders like Thalassemia requires a multi-pronged approach: ramping up screening efforts, bolstering awareness and counseling programs, and significantly expanding access to treatment facilities. These initiatives include organizing awareness camps, conducting medical screenings, and providing essential information about the disease to communities.

Moreover, the increased prevalence of thalassemia has indeed led to a higher demand for iron chelation therapy and folic acid supplements. Iron chelation therapy is essential in thalassemia patients to remove excess iron from the body and prevent complications such as organ damage, particularly in the heart and liver. The demand for iron chelators like deferasirox, deferiprone, and deferoxamine has increased with the rising prevalence of thalassemia cases.

For instance, in August 2020, according to the Ministry of Health and Family Welfare in India, the country has the highest prevalence of thalassemia globally, with approximately 150,000 individuals affected, and an estimated 10,000 to 15,000 children born with the condition annually. Furthermore, supplementing with folic acid helps to support red blood cell production and can alleviate some of the symptoms of anemia associated with thalassemia.

Thus, the increasing government initiatives are creating huge awareness of thalassemia among Indian population and rising incidences of thalassemia in India are burgeoning the growth of India thalassemia.

## **India Thalassemia Market Segment Insights**

### **India Thalassemia Type Insights**

Based on type, the India thalassemia market is segmented into alpha-thalassemia and beta-thalassemia. Beta-thalassemia held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2032. This is due to the factors such as rising prevalence of beta-thalassemia major (About 10,000 -15,000 babies with thalassemia major are born every year), growing emphasis on newborn screening programs for early identification and intervention, and increasing collaborations between pharmaceutical companies and research institutions.

### **India Thalassemia Treatment & Diagnosis Insights**

Based on treatment & diagnosis, the India thalassemia market has been segmented into treatment and diagnosis. The treatment segment further divided into blood transfusions, drugs, and folic acid supplements [immunoassay](../../../reports/immunoassay-market-5841) and diagnosis is bifurcated into instruments and reagents. Treatment held the largest market share in 2022 and diagnosis is anticipated to register the highest CAGR from 2022 to 2032. This growth is reflected due to some major factors such as rising prevalence of transfusion-dependent thalassemia patients, technological advancements in hemoglobinopathy testing, and advancements in genetic testing.

**FIGURE 2: INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2022 & 2032 (USD BILLION)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

**India Thalassemia Key Market Players & Competitive Insights**

The India thalassemia market is distinguished by the presence of numerous local players catering to thalassemia products that are evolving at a rapid pace. Furthermore, the rising prevalence of [type 2 diabetes](../../../reports/type-2-diabetes-mellitus-treatment-market-5669), increased prevalence of thalassemia, and sickle cell disease coupled with growing awareness among Indians is further driving the growth of India thalassemia market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products, services and signing contracts and agreements to broaden their reach and reduce operational costs.

Furthermore, Agios Pharmaceuticals Inc. (US) discovers and creates novel medications to treat rare genetic metabolic disorders and cancer. AG-946, a novel PKR activator for the treatment of sickle cell disease and hemolytic anemias, is one of its pipeline products. The drug candidate mitapivat is also part of the company's pipeline; it is intended to treat adult sickle cell disease, adult thalassemia, adult pyruvate kinase (PK) deficiency, adult thalassemia, and pediatric sickle cell disease. Adults with PK deficiency can treat their hemolytic anemia with tablets from Agios under the Pyrukynd brand.

The business provides the myAgios patient support services program, which consists of financial aid, prescription fulfillment, access support, illness education, and connections to the community. The company's strategic collaborations and financial strength position it well for continued growth and success in the biopharmaceutical industry. Furthermore, the company distributes its products through online channel across the world including India. Additionally, the company the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.

**Key Companies in the India Thalassemia Market includes.**

**India Thalassemia Market Industry Developments**

February 2022: The U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.

## **India Thalassemia Market Segmentation**

### **India Thalassemia Type Outlook**

### **India Thalassemia Treatment & Diagnosis Outlook**

## Market Drivers

### Rising Incidence of Thalassemia

The India Thalassemia Market is witnessing growth due to the rising incidence of thalassemia, particularly in certain regions such as Punjab and Gujarat. According to recent estimates, approximately 10,000 children are born with thalassemia each year in India, highlighting the urgent need for effective management and treatment options. This increasing prevalence is driving demand for blood transfusions, iron chelation therapies, and stem cell transplants. As awareness about the disease grows, more families are seeking genetic counseling and screening, further contributing to the market's expansion. The rising incidence of thalassemia not only underscores the need for comprehensive healthcare solutions but also presents opportunities for pharmaceutical companies to develop innovative therapies tailored to the needs of the Indian population.

### Government Initiatives and Policies

The India Thalassemia Market is significantly influenced by government initiatives aimed at combating thalassemia. The National Health Mission has implemented various programs to promote awareness and screening for thalassemia, particularly in high-prevalence regions. These initiatives include free screening for pregnant women and newborns, which has led to an increase in early diagnosis. Furthermore, the government has established guidelines for the management of thalassemia, ensuring that patients receive appropriate care. As a result, the market is expected to grow, with an estimated increase in the number of diagnosed cases leading to a higher demand for treatment options. This proactive approach by the government not only enhances patient outcomes but also stimulates the India Thalassemia Market by fostering a supportive environment for healthcare providers.

### Technological Advancements in Treatment

The India Thalassemia Market is being propelled by technological advancements in treatment options. Innovations such as gene therapy and novel drug formulations are emerging as potential game-changers in the management of thalassemia. For instance, recent clinical trials have shown promising results for gene editing techniques that could potentially cure thalassemia. Additionally, advancements in blood transfusion technology and iron chelation therapies are improving patient outcomes and quality of life. The introduction of these cutting-edge treatments is likely to attract investment and research in the India Thalassemia Market, as healthcare providers and patients alike seek more effective and less invasive options. This trend indicates a shift towards personalized medicine, which could redefine the landscape of thalassemia management in India.

### Increased Collaboration Among Stakeholders

The India Thalassemia Market is benefiting from increased collaboration among various stakeholders, including government bodies, non-governmental organizations, and healthcare providers. This collaborative approach is fostering a more integrated healthcare system that addresses the multifaceted challenges of thalassemia management. For example, partnerships between NGOs and hospitals are facilitating awareness campaigns and screening programs, which are crucial for early detection and intervention. Furthermore, these collaborations are enhancing access to treatment and support services for patients and their families. As stakeholders work together to create a more cohesive strategy for thalassemia care, the market is likely to experience growth driven by improved patient outcomes and increased access to necessary resources.

### Growing Investment in Healthcare Infrastructure

The India Thalassemia Market is poised for growth due to the increasing investment in healthcare infrastructure. The government and private sector are channeling resources into building specialized centers for thalassemia care, which are equipped with advanced diagnostic and treatment facilities. This investment is crucial, as it not only enhances the quality of care but also increases the capacity to manage a growing patient population. Additionally, the establishment of dedicated thalassemia clinics is likely to improve patient adherence to treatment protocols, thereby reducing complications associated with the disease. As healthcare infrastructure continues to develop, the India Thalassemia Market is expected to expand, providing better services and support for individuals affected by thalassemia.

## Future Outlook

The India Thalassemia Market is projected to grow at a 4.85% CAGR from 2025 to 2035, driven by advancements in gene therapy, increased awareness, and improved healthcare infrastructure.

**New opportunities:**

- Development of targeted gene therapies for thalassemia patients
- Expansion of mobile health applications for patient monitoring
- Establishment of specialized thalassemia treatment centers across urban areas

By 2035, the Thalassemia Market in India is expected to be robust and well-structured.

## Segment Insights

### By Treatment Type: Blood Transfusion (Largest) vs. Gene Therapy (Fastest-Growing)

In the India Thalassemia Market, the treatment landscape is predominantly shaped by Blood Transfusions, which holds the largest market share due to its longstanding application in managing Thalassemia symptoms. This method is essential, ensuring patients maintain adequate hemoglobin levels and reducing the complications associated with the disease. Following closely, Iron Chelation Therapy is vital in conjunction with transfusions to manage iron overload, while Bone Marrow Transplantation and Gene Therapy are emerging as crucial options, particularly for younger patients seeking long-term solutions.

Blood Transfusion (Dominant) vs. Gene Therapy (Emerging)

Blood Transfusion remains the dominant treatment strategy in the India Thalassemia Market, providing immediate relief and symptom management through regular transfusions. Families and hospitals have established robust protocols for this method, ensuring accessibility and reliability. In contrast, Gene Therapy is gaining traction as an innovative approach that offers the potential for a curative solution. Its emerging presence is attributed to advancements in biotechnology, sparking interest among patients and healthcare providers alike. The shift towards gene therapy highlights a growing trend in personalized medicine, indicating a future where Thalassemia might be resolved at a genetic level.

### By Patient Age Group: Pediatric (Largest) vs. Adult (Fastest-Growing)

In the India Thalassemia Market, the Pediatric segment commands the largest share, being critical as it encompasses the early diagnosis and management of thalassemia patients. This segment is vital for setting the foundation for long-term care and treatment, which enhances overall patient outcomes. The Adolescent and Adult segments also play significant roles, but their contributions to the market are comparatively lower, indicating a clear focus on pediatric care as the cornerstone of thalassemia management in India. 
The growth trends in this market segment are driven by increasing awareness about thalassemia and advancements in medical technology. The rising prevalence of thalassemia among children combined with effective screening programs encourages early intervention. Additionally, adult patients are emerging as a focus area, witnessing the fastest growth due to improved screening and management strategies tailored for older populations. This dual focus on pediatric and adult segments creates a comprehensive approach to thalassemia care in India.

Pediatric (Dominant) vs. Adult (Emerging)

The Pediatric segment is the dominant force in the India Thalassemia Market, characterized by a significant number of early diagnoses made through effective screening programs. This segment not only prioritizes timely treatment options but also focuses on lifestyle modifications and management strategies to enhance quality of life for young patients. Moreover, the care provided during this crucial developmental stage is instrumental in influencing long-term health outcomes. Conversely, the Adult segment is emerging as a critical area of growth, responding to the needs of a growing population of individuals living with thalassemia through innovative therapies and advanced management practices tailored for adults. This segment's evolution is supported by ongoing research and development efforts aimed at addressing the unique challenges faced by older patients, thus complementing the pediatric care framework.

### By Diagnosis Method: Hemoglobin Electrophoresis (Largest) vs. Genetic Testing (Fastest-Growing)

In the India Thalassemia Market, the diagnosis method segment is witnessing varied levels of adoption among its key players. Hemoglobin Electrophoresis holds the largest market share, serving as a vital diagnostic tool for identifying different types of thalassemia and their severity. Complete Blood Count also plays a significant role, providing crucial insights into hemoglobin levels but lacks the specificity offered by electrophoresis. In contrast, Genetic Testing, which provides comprehensive insight into genetic predisposition, is becoming an increasingly important method due to rising awareness and technological advancements in genomics.

Diagnostic Method: Hemoglobin Electrophoresis (Dominant) vs. Genetic Testing (Emerging)

Hemoglobin Electrophoresis is the dominant diagnostic method in India for thalassemia, celebrated for its precision in differentiating various hemoglobinopathies. Its established methodology ensures a high reliance among clinicians for effective diagnosis. Complete Blood Count remains an essential preliminary test; however, it often necessitates further investigation through more advanced methods like electrophoresis. On the other hand, Genetic Testing is emerging rapidly due to its role in early detection and personalized treatment plans. The increasing focus on genetic awareness and the reduction in costs associated with genetic tests are driving its growth, positioning it as a significant component of thalassemia diagnosis in the country.

### By Severity Level: Severe Thalassemia (Largest) vs. Mild Thalassemia (Fastest-Growing)

In the India Thalassemia Market, the severity level segments reveal a distinctive distribution of patient demographics, with Severe Thalassemia accounting for the largest share, reflecting significant health impacts on affected individuals. Moderate Thalassemia also holds a considerable market position, while Mild Thalassemia, which has often been overlooked, is emerging rapidly, driven by increased awareness and diagnosis rates in recent years. As healthcare systems adapt, Mild Thalassemia is gaining recognition, further diversifying the treatment landscape.

The growth trends within these segments indicate a shift towards comprehensive management strategies for all severity levels. Severe Thalassemia leads with established treatment protocols and ongoing research, while Mild Thalassemia experiences the fastest growth due to enhanced screening and preventive care initiatives. This evolution highlights a broader understanding among healthcare providers regarding the importance of addressing even mild cases, thereby driving market development and targeted medical solutions in India.

Severe Thalassemia (Dominant) vs. Mild Thalassemia (Emerging)

Severe Thalassemia is characterized by a significant clinical burden, requiring rigorous medical management and frequent interventions, making it the dominant segment in the India Thalassemia Market. Patients often experience severe symptoms necessitating blood transfusions and chelation therapy, leading to established care protocols and a strong reliance on specialized healthcare services. In contrast, Mild Thalassemia is becoming increasingly prominent, with its mild symptoms often going unnoticed. However, greater awareness and advances in genetic testing have propelled Mild Thalassemia into an emerging segment. This shift indicates an evolving healthcare landscape that recognizes the necessity for tailored therapeutic approaches even for the less severe cases, suggesting a potential future growth trajectory for treatment options and support tailored to this population.

## Competitive Benchmarking

The Thalassemia Market in India is characterized by a dynamic competitive landscape, driven by increasing awareness, advancements in treatment options, and a growing patient population. Major players such as Bristol Myers Squibb (US), Novartis (CH), and Roche (CH) are actively shaping the market through strategic initiatives. Bristol Myers Squibb (US) focuses on innovation in gene therapy, aiming to enhance treatment efficacy and patient outcomes. Novartis (CH) emphasizes partnerships with local healthcare providers to improve access to therapies, while Roche (CH) is investing in digital health solutions to streamline patient management and enhance treatment adherence. Collectively, these strategies contribute to a competitive environment that prioritizes patient-centric solutions and technological advancements.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several key players vying for market share. This fragmentation allows for diverse treatment options, but also intensifies competition among established and emerging companies. The collective influence of these players is significant, as they drive innovation and set industry standards.

In December 2025, Novartis (CH) announced a collaboration with a leading Indian biotechnology firm to develop a novel gene therapy for Thalassemia. This partnership is strategically important as it leverages local expertise and accelerates the development of tailored therapies for the Indian population, potentially enhancing treatment accessibility and affordability.

In November 2025, Roche (CH) launched a digital platform aimed at improving patient engagement and adherence to treatment protocols. This initiative is crucial as it aligns with the growing trend of digital health solutions, which are increasingly recognized for their role in enhancing patient outcomes and optimizing treatment pathways. By integrating technology into their offerings, Roche positions itself as a leader in patient-centric care.

In October 2025, Bristol Myers Squibb (US) expanded its clinical trial program in India, focusing on innovative therapies for Thalassemia. This expansion underscores the company's commitment to research and development in the region, potentially leading to breakthroughs that could redefine treatment paradigms. Such initiatives not only enhance the company's portfolio but also contribute to the overall advancement of Thalassemia care in India.

As of January 2026, current trends in the Thalassemia Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing treatment accessibility. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This shift indicates a promising future for the Thalassemia Market, where companies that prioritize innovation and patient-centric solutions may gain a competitive edge.

## Recent News & Developments

February 2022: The U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.

## Report Scope

| MARKET SIZE 2024 | 175.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 184.5(USD Million) |
| MARKET SIZE 2035 | 294.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.85% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer (US), Bayer (DE), Amgen (US), Sanofi (FR), Celgene (US), GSK (GB) |
| Segments Covered | Treatment Type, Patient Age Group, Diagnosis Method, Severity Level |
| Key Market Opportunities | Advancements in gene therapy and increased awareness drive growth in the India Thalassemia Market. |
| Key Market Dynamics | Rising awareness and advancements in gene therapy are transforming the Thalassemia treatment landscape in India. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India Thalassemia Market?**
A: The India Thalassemia Market was valued at 175.0 USD Million in 2024.

**Q: What is the projected market valuation for the India Thalassemia Market by 2035?**
A: The market is projected to reach 294.5 USD Million by 2035.

**Q: What is the expected CAGR for the India Thalassemia Market during the forecast period?**
A: The expected CAGR for the India Thalassemia Market from 2025 to 2035 is 4.85%.

**Q: Which treatment type generated the highest revenue in the India Thalassemia Market?**
A: Blood Transfusion generated the highest revenue, with a valuation range of 70.0 to 115.0 USD Million.

**Q: How does the market perform in terms of patient age groups?**
A: In 2024, the Adult age group accounted for a valuation of 85.0 to 144.5 USD Million.

**Q: What are the key diagnosis methods used in the India Thalassemia Market?**
A: Key diagnosis methods include Hemoglobin Electrophoresis, with a valuation range of 70.0 to 115.0 USD Million.

**Q: Which companies are leading the India Thalassemia Market?**
A: Key players include Bristol Myers Squibb, Novartis, Roche, and Pfizer.

**Q: What is the revenue range for Iron Chelation Therapy in the market?**
A: Iron Chelation Therapy had a revenue range of 50.0 to 80.0 USD Million in 2024.

**Q: How does the market segment by severity level?**
A: In 2024, Severe Thalassemia had a revenue range of 70.0 to 126.5 USD Million.

**Q: What is the projected growth trend for the India Thalassemia Market?**
A: The market is expected to grow steadily, reaching 294.5 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-thalassemia-market-22054*